Key diabetes drug price crashes by up to 90% as generics enter market

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma companies launched generic versions of this Boehringer Ingelheim (BI) drug, which went off patent earlier this month. The move will make the drug more accessible to India’s diabetic patients, and eventually grow the market by five-six-fold in volumes, industry insiders felt. The innovator drug named Jardiance by BI costs around ₹60 per tablet.

 

Delhi-based Mankind Pharma launched a range of empagliflozin products, including its combinations, priced between ₹5.5 and ₹13.5 per tablet. On the same day, Mumbai-based Glenmark Pharmaceuticals